Drug Trial Radar · NCT02980016
Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive Individuals
Last checked: Nov 19, 2026Latest source record: Oct 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,027
Actual
Start
Nov 2016
Primary completion
Oct 18, 2019
Study completion Oct 18, 2019
Sponsor
- Lead sponsor
- The Aurum Institute NPCAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Aurum Institute; London School of Hygiene and Tropical Medicine; Johns Hopkins University
- First posted
- Dec 2, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a parallel, two part, open label, individually randomized, pragmatic trial among HIV-positive individuals. Part A compares a single round of weekly high dose rifapentine plus isoniazid for three months (3HP) to six months of daily isoniazid (6H). Part B compares periodic 3HP (p3HP) to a single round of 3HP.
Conditions
- Tuberculosis
- HIV
Interventions
rifapentine + isoniazidDrug
Rifapentine + isoniazid Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), with adjustment for participants weighing ≤50 kg
IsoniazidDrug
Daily self-administered isoniazid (at a dose of 300 mg/daily), with adjustment for participants weighing ≤24 kg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment completion (part A)Time frame: 1 year
- TB incidence (part B)Time frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Aurum Institute NPC
Johannesburg, Gauteng, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.